Apretude

Apretude is an injectable medication containing cabotegravir, used for HIV-1 pre-exposure prophylaxis (PrEP). This long-acting formulation is administered intramuscularly to help prevent HIV infection in at-risk individuals.

Apretude is primarily used for HIV-1 pre-exposure prophylaxis (PrEP) in adults and adolescents weighing at least 35 kg. It is designed for individuals at risk of HIV-1 infection who may have difficulty adhering to daily oral medication regimens. The medication works by blocking the virus from replicating in the body, providing long-lasting protection.

Common effects of Apretude may include injection site reactions such as pain, tenderness, redness, and swelling. Some individuals may also experience headaches, fever, fatigue, and muscle aches. These effects are generally mild to moderate and may resolve over time.

Apretude should be used with caution in individuals with a history of liver disease or hepatitis. It is important to discuss all current medications with a healthcare provider before starting Apretude, as it may interact with certain drugs. Regular monitoring and follow-up appointments are recommended to ensure the medication's effectiveness and safety.

Apretude may interact with other medications, including those metabolized by the liver enzymes CYP3A. It is important to inform a healthcare provider about all current medications, including over-the-counter drugs, supplements, and herbal products. Alcohol consumption should be discussed with a healthcare provider, as it may affect the body's response to the medication.